AstraZeneca plc (ADR) (AZN)
The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Recs
Recs
abacusdude
(91.87)
Submitted: 8/19/2008 6:59:15 PM :
Start Price:
$45.44
AZN Score:
+10.90
No matter what the economy is like, people still need to take their medication.
Recs
atsfstan
(38.09)
Submitted: 7/24/2009 11:10:22 AM :
Start Price:
$46.72
AZN Score:
-15.95
10 years of growth and increased profitability. Is maintaining position though an active R&D program. Good cash flow considering stock biy back program (active since early 2001). I like this stock to be an attractive investment for anyone interested in a positon in the medical field.
Recs
bearmyx
(93.58)
Submitted: 5/4/2007 6:20:58 PM :
Start Price:
$48.63
AZN Score:
+16.36
near 52 week lows,
Recs
boca7rel
(75.97)
Submitted: 5/26/2007 3:08:29 PM :
Start Price:
$47.98
AZN Score:
+18.15
cheap earnings compared to industry sector. Low debt to equity ratio
Recs
BreakerBeth
(81.32)
Submitted: 5/18/2006 12:27:18 PM :
Start Price:
$46.93
AZN Score:
+3.96
Among the other things I like about AZN, if it gains FDA approval to promote Seroquel for bipolar disorder, I think that will open up a huge market. There's a big educational project underway to raise awareness about bipolar-2 -- the likely culprit in many who are diagnosed with unipolar depression. Since SSRIs either fail or make bipolar-2's worse, the market for an effective treatment with a low side effect profile is huge. Could Seroquel fill the bill?
Recs
btarabishy
(< 20)
Submitted: 12/20/2006 3:26:54 PM :
Start Price:
$47.35
AZN Score:
+13.85
Unfairly undervalued compared to its peers. Blockbuster portfolio and heading in the right directions in its pipelines. Expect the stock to recover with strong sales in 07.
Recs
BUYBELOW
(< 20)
Submitted: 6/18/2007 5:00:48 PM :
Start Price:
$46.67
AZN Score:
+21.43
A Value play that pays as you wait . Low p/e compared to its peers.
Recs
catmon
(66.27)
Submitted: 6/19/2008 3:55:23 PM :
Start Price:
$39.31
AZN Score:
+30.77
Arimidex use will increase sales with favorable ATAC trial released.
Recs
cecil97
(< 20)
Submitted: 7/14/2009 10:56:04 PM :
Start Price:
$44.19
AZN Score:
-16.44
H1N1 vaccine demand, low forward P/E, consistent earnings and generous dividend. Next earnings report is 7/30/09
Recs
Chipperfield
(79.89)
Submitted: 4/14/2009 3:33:44 PM :
Start Price:
$34.03
AZN Score:
+2.21
Big Ph. is trading as historically cheap levels.
Recs
Clint35
(67.69)
Submitted: 2/21/2009 10:50:06 PM :
Start Price:
$35.06
AZN Score:
-13.30
They're margins are great. The P/E is low and they raised their dividend not long ago.
Recs
clu2000
(79.77)
Submitted: 10/26/2006 2:38:35 PM :
Start Price:
$54.04
AZN Score:
+0.26
earnings continue to rise, despite one drug not working
Recs
cnj01
(65.10)
Submitted: 9/22/2009 12:03:49 PM :
Start Price:
$46.19
AZN Score:
-4.11
Top notch pharmaceutical
Recs
daddylonglegs9
(67.46)
Submitted: 5/10/2008 3:59:01 PM :
Start Price:
$38.39
AZN Score:
+36.37
Astra zeneca has superior patient assistance programs enabling them to get an ever increasing share od Government perscription drug programs
Recs
delocin
(< 20)
Submitted: 4/27/2008 4:49:54 PM :
Start Price:
$39.85
AZN Score:
+32.39
Two words: baby boomers. As boomers age, the drugs made by AstraZeneca will become more necessary. I expect this stock to double in the next 7-10 years. Of course, as new drugs come out and go through their trials with the FDA, or lose their patent protection, the stock will bounce around, generally going higher.
Recs
designedfor
(76.11)
Submitted: 12/14/2006 8:59:40 PM :
Start Price:
$49.68
AZN Score:
+9.74
great pipeline of anti tumor drugs
Recs
deuspecuniae
(74.25)
Submitted: 5/1/2008 12:11:16 PM :
Start Price:
$38.98
AZN Score:
+34.80
The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.
Recs
englandstumpy
(31.57)
Submitted: 3/30/2009 3:15:12 PM :
Start Price:
$33.76
AZN Score:
-7.03
Crestor looks like a good contributor. Current price depressed.
Recs
equalfuture
(38.62)
Submitted: 3/17/2008 7:15:17 PM :
Start Price:
$34.01
AZN Score:
+45.75
TOUGH MARKET, BUT SHOULD HOLD ITS OWN
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 72 1 2 3 4 Next »